This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Boom Or Bubble? Insiders Like The Look Of These 3 Biotech Stocks

3. ACADIA Pharmaceuticals, Inc. ( ACAD): Focuses on drug discovery and clinical development of novel treatments for central nervous system disorders.

Market cap at $1.755B, most recent closing price at $20.89.

Over the last six months, insiders were net buyers of 3,964,834 shares, which represents about 8.04% of the company's 49.34M share float.

ACADIA Pharmaceuticals has returned -23.80% since October 7 th, falling considerably behind several industry peers including Gilead Sciences and Amgen, which returned 9.05% and 2.82% during the same time period.

In the pipeline:

During the company's third quarter earnings call, CEO Uli Hacksell stated that ACADIA is on track to submit a new drug application for its pimavanserin medication - specifically for the treatment of Parkinson's disease psychosis (PDP) – to the FDA near the end of 2014.

Pimavanserin is also in clinical trials for the treatment of schizophrenia and Alzheimer's disease psychosis; ACADIA completed its Phase 2 trial for schizophrenia last year and will commence the Phase 2 trial for Alzheimer's disease psychosis (ADP) this month. Currently no drugs have been approved for the treatment of either PDP or ADP in the US.

 

 

( List compiled by Mary-Lynn Cesar, a Kapitall Writer. Insider data sourced from Yahoo! Finance. Analyst ratings data sourced from Zacks Investment Research. All other data sourced from Finviz)

null
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs